PMID- 34757263
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240220
IS  - 1525-5069 (Electronic)
IS  - 1525-5050 (Linking)
VI  - 124
DP  - 2021 Oct 28
TI  - Tolerability of antiseizure medicines using Lithuanian version of the Liverpool 
      Adverse Events Profile.
PG  - 108371
LID - S1525-5050(21)00632-6 [pii]
LID - 10.1016/j.yebeh.2021.108371 [doi]
AB  - OBJECTIVES: To develop and validate a Lithuanian version of the Liverpool Adverse 
      Events Profile (LT-LAEP), and to evaluate the main demographic, clinical, and 
      pharmacological determinants of its score. MATERIALS AND METHODS: We developed 
      the LT-LAEP and examined its psychometric properties. People with epilepsy (PWE) 
      were asked to fill in the LT-LAEP, the Generalized Anxiety Disorder scale-7 
      (GAD-7), the Neurological Disorders Depression Inventory for Epilepsy (NDDI-E), 
      and a questionnaire addressing key demographic and clinical information. 
      Antiseizure medicine (ASM) burden was expressed as a number of ASM and total drug 
      load. Multiple linear regression analysis was used to determine the influence of 
      various variables on LAEP results. RESULTS: The data of 157 participants with the 
      established diagnosis of epilepsy and stable ASM regimen were included in the 
      final analysis. The mean LT-LAEP score was 48.72 +/- 13.65. High internal 
      consistency (Cronbach's alpha = 0.912) and test-retest reliability (ICC = 0.801) were 
      demonstrated. The most common adverse effects (AEs) were tiredness (24.8%) and 
      memory problems (23.6%). Lithuanian version of the Liverpool Adverse Events 
      Profile score significantly correlated with NDDI-E (r = 0.635, p < 0.001) and 
      GAD-7 (r = 0.640, p < 0.001) scores. The correlation between LT-LAEP score and 
      total drug load was weak (r = 0.243, p = 0.002). The significant predictors of 
      higher LT-LAEP score were female sex (beta = -4.768, p = 0.003), higher seizure 
      frequency (beta = 4.757, p < 0.001), and higher NDDI-E (beta = 1.457, p < 0.001) and 
      GAD-7 scores (beta = 0.610, p = 0.007) (F(4,152) = 43.975, R(2) = 0.536, p < 0.001). 
      CONCLUSIONS: The LT-LAEP is a reliable and valid instrument for the evaluation of 
      the AEs of ASM. A higher score of LT-LAEP is predicted by female sex, seizure 
      frequency, and anxiety and depression levels rather than total drug load.
CI  - Copyright (c) 2021 Elsevier Inc. All rights reserved.
FAU - Jasionis, Arminas
AU  - Jasionis A
AD  - Vilnius University, Center for Neurology, Vilnius, Lithuania.
FAU - Jasionyte, Gabija
AU  - Jasionyte G
AD  - Vilnius University, Faculty of Medicine, Vilnius, Lithuania.
FAU - Mameniskiene, Ruta
AU  - Mameniskiene R
AD  - Vilnius University, Center for Neurology, Vilnius, Lithuania. Electronic address: 
      ruta.mameniskiene@santa.lt.
LA  - eng
PT  - Journal Article
DEP - 20211028
PL  - United States
TA  - Epilepsy Behav
JT  - Epilepsy & behavior : E&B
JID - 100892858
SB  - IM
OTO - NOTNLM
OT  - Adverse effects
OT  - Adverse events profile
OT  - Antiseizure medicines
OT  - Anxiety
OT  - Depression
OT  - Epilepsy
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2021/11/11 06:00
MHDA- 2021/11/11 06:01
CRDT- 2021/11/10 15:47
PHST- 2021/05/05 00:00 [received]
PHST- 2021/09/20 00:00 [revised]
PHST- 2021/09/25 00:00 [accepted]
PHST- 2021/11/11 06:01 [medline]
PHST- 2021/11/11 06:00 [pubmed]
PHST- 2021/11/10 15:47 [entrez]
AID - S1525-5050(21)00632-6 [pii]
AID - 10.1016/j.yebeh.2021.108371 [doi]
PST - aheadofprint
SO  - Epilepsy Behav. 2021 Oct 28;124:108371. doi: 10.1016/j.yebeh.2021.108371.